DE69524592D1 - 2-Acylaminopropanolverbindung und ihre pharmazeutische Zusammensetzung - Google Patents

2-Acylaminopropanolverbindung und ihre pharmazeutische Zusammensetzung

Info

Publication number
DE69524592D1
DE69524592D1 DE69524592T DE69524592T DE69524592D1 DE 69524592 D1 DE69524592 D1 DE 69524592D1 DE 69524592 T DE69524592 T DE 69524592T DE 69524592 T DE69524592 T DE 69524592T DE 69524592 D1 DE69524592 D1 DE 69524592D1
Authority
DE
Germany
Prior art keywords
pharmaceutical composition
acylaminopropanol compound
acylaminopropanol
compound
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69524592T
Other languages
English (en)
Other versions
DE69524592T2 (de
Inventor
Jinichi Inokuchi
Masayuki Jinbo
Takayuki Nagai
Haruki Yamada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seikagaku Corp
Original Assignee
Seikagaku Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seikagaku Corp filed Critical Seikagaku Corp
Application granted granted Critical
Publication of DE69524592D1 publication Critical patent/DE69524592D1/de
Publication of DE69524592T2 publication Critical patent/DE69524592T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
DE69524592T 1994-06-10 1995-06-07 2-Acylaminopropanolverbindung und ihre pharmazeutische Zusammensetzung Expired - Lifetime DE69524592T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP12873494 1994-06-10
PCT/JP1995/001143 WO1995034530A1 (fr) 1994-06-10 1995-06-07 Compose de 2-acylaminopropanol et composition medicinale

Publications (2)

Publication Number Publication Date
DE69524592D1 true DE69524592D1 (de) 2002-01-24
DE69524592T2 DE69524592T2 (de) 2002-07-18

Family

ID=14992137

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69524592T Expired - Lifetime DE69524592T2 (de) 1994-06-10 1995-06-07 2-Acylaminopropanolverbindung und ihre pharmazeutische Zusammensetzung

Country Status (8)

Country Link
US (1) US5763438A (de)
EP (1) EP0765865B1 (de)
JP (1) JP3850437B2 (de)
CN (1) CN1152907A (de)
AU (1) AU698833B2 (de)
CA (1) CA2192555C (de)
DE (1) DE69524592T2 (de)
WO (1) WO1995034530A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO965193L (no) * 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
EP1098642B1 (de) * 1998-07-27 2007-04-04 Johns Hopkins University Diamino-propanol-verbindungen zur behandlung von ischaemien
EP1384719A1 (de) * 1999-07-09 2004-01-28 The Regents of The University of Michigan Inhibitoren des Glykosylzeramidsynthase-Enzyms für die Behandlung von Krebs, Sphingolipidosis und mikrobiellen Infektionen
US6407064B2 (en) * 1999-12-06 2002-06-18 Seikagaku Corporation Aminoalcohol derivative and medicament comprising the same
US6626961B1 (en) 2000-04-27 2003-09-30 Kimberly-Clark Worldwide, Inc. Nonwovens modified with petrolatum
JP2004531478A (ja) * 2001-01-10 2004-10-14 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン アミノセラミド様化合物および治療目的での使用方法
DK2067775T3 (da) 2001-07-16 2012-07-16 Genzyme Corp N-acylsphingosinglucosyltransferase-inhibitor
IL160850A0 (en) * 2001-09-26 2004-08-31 Yissum Res Dev Co Sphingolipids
US20060217560A1 (en) * 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
US6916802B2 (en) * 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20090111812A1 (en) * 2004-06-14 2009-04-30 Musc Foundation For Research Development Methods for treating inflammatory disorders
RU2007110731A (ru) * 2004-09-23 2008-10-27 Редди Юс Терапевтикс Новые соединения пиримидина, способ их получения и содержащие их композиции
CA2586761A1 (en) * 2004-11-10 2006-05-18 Genzyme Corporation Methods of treating diabetes mellitus
US20090088433A1 (en) 2005-01-26 2009-04-02 Bertrand Leblond Methods of using as analgesics 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
HUE026057T2 (en) 2006-05-09 2016-05-30 Genzyme Corp Procedures for the Treatment of Fatty Liver Disease, which comprises inhibition of glycosphingolipid synthesis
US8304447B2 (en) 2007-05-31 2012-11-06 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
SG10201707161PA (en) 2007-10-05 2017-10-30 Genzyme Corp Method of treating polycystic kidney diseases with ceramide derivatives
EP2116139A1 (de) * 2008-05-08 2009-11-11 Nestec S.A. Sialisäure zur Stärkung der Gehirngesundheit bei älteren Menschen
WO2010014554A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
CN107935983A (zh) 2008-10-03 2018-04-20 简詹姆公司 2‑酰胺基丙醇型葡糖神经酰胺合酶抑制剂
SI2796457T1 (sl) 2009-11-27 2016-10-28 Genzyme Corporation Genz 112638 za zdravljenje Gaucherjeve ali Fabryjeve bolezni v kombinirani terapiji

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041441A (en) * 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
DE3941235A1 (de) * 1989-12-14 1991-06-20 Bayer Ag Neue peptide, ihre herstellung und ihre verwendung in arzneimitteln
AU8231391A (en) * 1990-07-06 1992-02-04 Smithkline Beecham Corporation Inhibitors of aspartic proteases
EP0558673B1 (de) * 1990-11-19 1996-04-17 Monsanto Company Retrovirale proteaseinhibitoren
US5302609A (en) * 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
WO1994027607A1 (fr) * 1993-05-28 1994-12-08 Seikagaku Corporation Agent antiviral
US5916911A (en) * 1995-09-20 1999-06-29 The Regents Of The University Of Michigan Amino ceramide--like compounds and therapeutic methods of use

Also Published As

Publication number Publication date
DE69524592T2 (de) 2002-07-18
CA2192555C (en) 2005-01-11
US5763438A (en) 1998-06-09
EP0765865A4 (de) 1997-08-13
CN1152907A (zh) 1997-06-25
JP3850437B2 (ja) 2006-11-29
EP0765865B1 (de) 2001-12-12
CA2192555A1 (en) 1995-12-21
WO1995034530A1 (fr) 1995-12-21
EP0765865A1 (de) 1997-04-02
AU2630295A (en) 1996-01-05
AU698833B2 (en) 1998-11-12

Similar Documents

Publication Publication Date Title
BR9500784A (pt) Composto e formulação farmacêutica
BR9504060A (pt) Composto e formulação farmacêutica
DE69618587T2 (de) Chinazoline und pharmazeutische zusammensetzungen
DE69524592T2 (de) 2-Acylaminopropanolverbindung und ihre pharmazeutische Zusammensetzung
BR1100824A (pt) Composto e composição farmacêutica
DE69525148T2 (de) Pharmazeutische formulierung
KR950703566A (ko) 티에노디아제핀 화합물 및 그의 의약 용도[thienodiazepine compound and medicinal use thereof]
FI944832A (fi) Farmaseuttinen koostumus
BR9707501A (pt) Composto composição farmacêutica e uso do composto
DE69618663T2 (de) O-carbamoyl-phenylalaninol-zusammensetzungen und ihre pharmazeutisch anwendbaren salzen
DE69704060T2 (de) Tetrahydroisochinolinderivate und ihre pharmazeutische anwendung
BR9707808A (pt) Composto composição farmacêutica e uso do composto
ITMI932540A0 (it) Composizione farmaceutica
BR9509688A (pt) Composto e composição farmacêutica
DE4294862T1 (de) Pharmazeutische Komposition
DE59801987D1 (de) Pharmazeutische zusammensetzung enthaltend peptichemio
BR9507768A (pt) Composição farmacêutica
BR9612413A (pt) Composto uso do mesmo e composição farmacêutica
ID18698A (id) Komposisi farmasi
DE69509621D1 (de) Diarylheptanoidderivat und diese enthaltende pharmazeutische Zusammensetzung
ITMI962628A0 (it) Composizione farmaceutica
DE69900336T2 (de) Pentoxifyllin und antizytokin enthaltende pharmazeutische zusammensetzungen
BR9505130A (pt) Composto e composiçao farmacêutica
IT1272935B (it) Composizione farmaceutica contenente n-acetil-cisteina
BR9500539A (pt) Composto farmacêutico e composição farmacêutica

Legal Events

Date Code Title Description
8364 No opposition during term of opposition